Research graph
References from Neurotoxicity and cognitive outcomes in modern therapies for primary central nervous system lymphoma. Local targets link to admitted publications; unresolved targets remain external evidence.
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)
10.1093/neuonc/noac196 · 2023 · External reference
Management and outcome of primary CNS lymphoma in the modern era: An LOC network study
10.1212/wnl.0000000000008900 · 2020 · External reference
Delayed neurotoxicity in primary central nervous system lymphoma
10.1001/archneur.62.10.1595 · 2005 · External reference
Long-term survival in primary CNS lymphoma
10.1200/jco.1998.16.3.859 · 1998 · External reference
Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients age 60 years and younger: long-term results of the randomized phase II PRECIS Study
10.1200/jco.22.00491 · 2022 · External reference
Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma
10.1093/neuonc/noaf221 · 2026 · External reference
Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study
10.1182/bloodadvances.2022007011 · 2022 · External reference
Consolidation reduced-dose whole-brain radiation therapy with response-adapted boost in older patients with newly diagnosed primary central nervous system lymphoma
10.1007/s11060-026-05456-z · 2026 · External reference
Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial
10.1093/neuonc/noab021 · 2021 · External reference
Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation
10.1007/s11060-019-03257-1 · 2019 · External reference
Consolidation regimen and cerebral atrophy in patients with primary central nervous system lymphoma
10.1016/j.ijrobp.2024.11.088 · 2025 · External reference
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial
10.1016/s2352-3026(17)30174-6 · 2017 · External reference
Long-term outcomes in primary CNS lymphoma after R-MVP and high-dose chemotherapy with autologous hematopoietic stem cell transplant
10.1212/wnl.0000000000207490 · 2023 · External reference
Association of MTHFR polymorphisms with leukoencephalopathy risk in patients with primary CNS lymphoma treated with methotrexate-based regimens
10.1212/wnl.0000000000207670 · 2023 · External reference
Clinical relevance of brain MRI changes in primary central nervous system lymphoma after high-dose-chemotherapy and autologous stem cell transplantation
10.1038/s41409-024-02382-4 · 2024 · External reference
High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial
10.1016/s2352-3026(23)00371-x · 2024 · External reference
CAR-T cells for the treatment of central nervous system tumours: known and emerging neurotoxicities
10.3390/brainsci14121220 · 2024 · External reference
CAR T-cell therapy for central nervous system lymphoma
10.1007/s11912-024-01609-3 · 2024 · External reference
Neurotoxicity in patients with CNS lymphomas treated with CAR T-cell therapy: a study from the French Oculo-Cerebral Lymphoma Network
10.1212/wnl.0000000000213501 · 2025 · External reference
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells
10.1093/neuonc/noad118 · 2023 · External reference
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial
10.1182/blood.2021014738 · 2022 · External reference
CAR T-cell therapy in patients with primary central nervous system lymphoma: a LOC Network Study
10.1002/ajh.70375 · 2026 · External reference
Tumor inflammation-associated neurotoxicity
10.1038/s41591-023-02276-w · 2023 · External reference
Car T-cell therapy does not lead to mediumterm neurocognitive deterioration in patients with central nervous system lymphomas. A LOC network study
2025 · External reference
Toxicities associated with lymphoma-targeting bispecific antibodies—a review
10.3389/fmed.2025.1582975 · 2025 · External reference
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
10.1182/blood.2023022432 · 2024 · External reference
Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma
10.1038/s41408-026-01519-6 · 2026 · External reference
Multicenter real-world analysis of glofitamab in relapsed/refractory primary CNS lymphoma: clinical activity, CNS penetration, and CTDNA dynamics
10.1002/ajh.70342 · 2026 · External reference
Safety and efficacy of CD3xCD20 bispecific antibody for the treatment of primary and secondary central nervous system lymphoma patients: a multicentric retrospective study
10.1182/blood-2025-1018 · 2025 · External reference
Primary central nervous system lymphomas in immunocompromised patients require specific response criteria
10.1007/s11060-024-04694-3 · 2024 · External reference
Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: a RANO review
10.1093/neuonc/noae032 · 2024 · External reference
Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL)
10.1093/neuonc/nor203 · 2012 · External reference
Cerebrospinal fluid interleukin-10 may be a useful biomarker for atypical primary central nervous system lymphoma relapse
10.1016/j.neurol.2020.08.004 · 2021 · External reference
The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients
10.1016/j.ejca.2016.03.080 · 2016 · External reference
Mild metabolism increase on posttreatment 18F-FDG PET may indicate recurrence of primary CNS lymphoma
10.1097/rlu.0000000000005948 · 2025 · External reference
Combining MYD88 L265P mutation detection and clonality determination on CSF cellular and cell-free DNA improves diagnosis of primary CNS lymphoma
10.1111/bjh.18758 · 2023 · External reference
Interim FDG-PET improves treatment failure prediction in primary central nervous system lymphoma: an LOC network prospective multicentric study
10.1093/neuonc/noae029 · 2024 · External reference
Prognostic value of 18F-FDG PET in primary central nervous system lymphoma: assessing interim metabolic response for improving patient stratification
10.1097/rlu.0000000000005703 · 2025 · External reference
Delayed neurotoxicity in primary central nervous system lymphoma
10.1001/archneur.62.10.1595 · ExternalCitation · doi-reference
Multicenter real-world analysis of glofitamab in relapsed/refractory primary CNS lymphoma: clinical activity, CNS penetration, and CTDNA dynamics
10.1002/ajh.70342 · ExternalCitation · doi-reference
CAR T-cell therapy in patients with primary central nervous system lymphoma: a LOC Network Study
10.1002/ajh.70375 · ExternalCitation · doi-reference
Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation
10.1007/s11060-019-03257-1 · ExternalCitation · doi-reference
Primary central nervous system lymphomas in immunocompromised patients require specific response criteria
10.1007/s11060-024-04694-3 · ExternalCitation · doi-reference
Consolidation reduced-dose whole-brain radiation therapy with response-adapted boost in older patients with newly diagnosed primary central nervous system lymphoma
10.1007/s11060-026-05456-z · ExternalCitation · doi-reference
CAR T-cell therapy for central nervous system lymphoma
10.1007/s11912-024-01609-3 · ExternalCitation · doi-reference
The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients
10.1016/j.ejca.2016.03.080 · ExternalCitation · doi-reference
Consolidation regimen and cerebral atrophy in patients with primary central nervous system lymphoma
10.1016/j.ijrobp.2024.11.088 · ExternalCitation · doi-reference
Cerebrospinal fluid interleukin-10 may be a useful biomarker for atypical primary central nervous system lymphoma relapse
10.1016/j.neurol.2020.08.004 · ExternalCitation · doi-reference
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial
10.1016/s2352-3026(17)30174-6 · ExternalCitation · doi-reference
High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial
10.1016/s2352-3026(23)00371-x · ExternalCitation · doi-reference
Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma
10.1038/s41408-026-01519-6 · ExternalCitation · doi-reference
Clinical relevance of brain MRI changes in primary central nervous system lymphoma after high-dose-chemotherapy and autologous stem cell transplantation
10.1038/s41409-024-02382-4 · ExternalCitation · doi-reference
Tumor inflammation-associated neurotoxicity
10.1038/s41591-023-02276-w · ExternalCitation · doi-reference
Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial
10.1093/neuonc/noab021 · ExternalCitation · doi-reference
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)
10.1093/neuonc/noac196 · ExternalCitation · doi-reference
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells
10.1093/neuonc/noad118 · ExternalCitation · doi-reference
Interim FDG-PET improves treatment failure prediction in primary central nervous system lymphoma: an LOC network prospective multicentric study
10.1093/neuonc/noae029 · ExternalCitation · doi-reference
Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: a RANO review
10.1093/neuonc/noae032 · ExternalCitation · doi-reference
Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma
10.1093/neuonc/noaf221 · ExternalCitation · doi-reference
Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL)
10.1093/neuonc/nor203 · ExternalCitation · doi-reference
Prognostic value of 18F-FDG PET in primary central nervous system lymphoma: assessing interim metabolic response for improving patient stratification
10.1097/rlu.0000000000005703 · ExternalCitation · doi-reference
Mild metabolism increase on posttreatment 18F-FDG PET may indicate recurrence of primary CNS lymphoma
10.1097/rlu.0000000000005948 · ExternalCitation · doi-reference
Combining MYD88 L265P mutation detection and clonality determination on CSF cellular and cell-free DNA improves diagnosis of primary CNS lymphoma
10.1111/bjh.18758 · ExternalCitation · doi-reference
Safety and efficacy of CD3xCD20 bispecific antibody for the treatment of primary and secondary central nervous system lymphoma patients: a multicentric retrospective study
10.1182/blood-2025-1018 · ExternalCitation · doi-reference
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial
10.1182/blood.2021014738 · ExternalCitation · doi-reference
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
10.1182/blood.2023022432 · ExternalCitation · doi-reference
Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study
10.1182/bloodadvances.2022007011 · ExternalCitation · doi-reference
Long-term survival in primary CNS lymphoma
10.1200/jco.1998.16.3.859 · ExternalCitation · doi-reference
Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients age 60 years and younger: long-term results of the randomized phase II PRECIS Study
10.1200/jco.22.00491 · ExternalCitation · doi-reference
Management and outcome of primary CNS lymphoma in the modern era: An LOC network study
10.1212/wnl.0000000000008900 · ExternalCitation · doi-reference
Long-term outcomes in primary CNS lymphoma after R-MVP and high-dose chemotherapy with autologous hematopoietic stem cell transplant
10.1212/wnl.0000000000207490 · ExternalCitation · doi-reference
Association of MTHFR polymorphisms with leukoencephalopathy risk in patients with primary CNS lymphoma treated with methotrexate-based regimens
10.1212/wnl.0000000000207670 · ExternalCitation · doi-reference
Neurotoxicity in patients with CNS lymphomas treated with CAR T-cell therapy: a study from the French Oculo-Cerebral Lymphoma Network
10.1212/wnl.0000000000213501 · ExternalCitation · doi-reference
Toxicities associated with lymphoma-targeting bispecific antibodies—a review
10.3389/fmed.2025.1582975 · ExternalCitation · doi-reference
CAR-T cells for the treatment of central nervous system tumours: known and emerging neurotoxicities
10.3390/brainsci14121220 · ExternalCitation · doi-reference
